United States Patent 8,754,065: Tenofovir Alafenamide Hemifumarate Claims, Scope, Expiration and Competitive Patent Landscape
U.S. Patent No. 8,754,065 protects tenofovir alafenamide hemifumarate, selected solid-state characteristics, pharmaceutical compositions, HIV and HBV treatment methods, and seeded crystallization processes. The patent is assigned to Gilead Sciences and is directed primarily to the salt form used in tenofovir alafenamide products, including Vemlidy and combination antiretroviral products. Its strongest commercial claims are the composition-of-matter salt claim, the solid-form characterization claims, and the manufacturing claims.
The patent issued June 17, 2014, from an application filed September 28, 2012, with a claimed priority date in 2011. The ordinary projected patent-term endpoint is in 2032, subject to any patent-term adjustment, terminal disclaimer, or other USPTO correction appearing in the official record.[1]
What does U.S. Patent 8,754,065 protect?
The patent has four principal claim groups:
| Claim group |
Claims |
Protected subject matter |
Commercial significance |
| Salt composition |
1-5 |
Tenofovir alafenamide hemifumarate and defined DSC/XRPD characteristics |
Highest value; potentially blocks manufacture or sale of the claimed salt form |
| Salt-containing compositions |
6-16 |
Approximately 0.5:1 fumaric acid-to-TAF ratio, solid compositions, excipients and additional HIV agents |
Relevant to drug products and fixed-dose combinations |
| Therapeutic methods |
17-25 |
HIV and HBV treatment using the hemifumarate, including once- or multiple-daily dosing |
Potential method-of-use protection, subject to statutory and litigation limitations |
| Manufacturing processes |
26-31 |
Formulation preparation and seeded crystallization using specified solvents and temperatures |
Relevant to API and finished-product manufacturing routes |
Claim 1 is the central claim. It broadly recites “tenofovir alafenamide hemifumarate” without limiting the salt to a particular crystal form, particle size, purity, solvent content, or manufacturing process.
Claims 2 through 5 narrow the protected material by physical characterization. Claims 6 through 16 target compositions containing the salt. Claims 27 through 31 cover particular crystallization methods.
How broad is claim 1 to tenofovir alafenamide hemifumarate?
Claim 1 is a composition-of-matter claim to the hemifumarate salt of tenofovir alafenamide, also known as TAF. A hemifumarate generally indicates a stoichiometric relationship of approximately two molecules of TAF to one molecule of fumaric acid.
The claim does not expressly require:
- A particular DSC profile;
- Specific XRPD peaks;
- A particular solvent;
- A seed crystal;
- A specific particle-size distribution;
- A pharmaceutical excipient;
- A particular tablet strength;
- A fixed-dose combination; or
- Use in HIV or HBV treatment.
That breadth makes claim 1 the most important claim for product-level freedom-to-operate analysis. A product containing the same TAF hemifumarate salt could potentially fall within claim 1 even if it was made by a different process or formulated with different excipients.
The principal infringement issue would be chemical identity. A competing product using a different TAF salt, a non-salt form of TAF, or a chemically distinct prodrug would require a separate analysis. A formulation that converts to the hemifumarate during manufacturing or storage could create additional risk, depending on the claim construction and evidence of the final product’s composition.
What do claims 2 through 5 protect?
Claims 2 through 5 add analytical limitations based on DSC and XRPD data.
DSC claims
Claim 2 covers hemifumarate having a DSC onset endotherm of 131 ± 2°C, effectively a range of approximately 129°C to 133°C.
Claim 3 narrows the range to 131 ± 1°C, or approximately 130°C to 132°C.
These claims may identify a particular crystalline or thermally characterized form. Their enforceability depends on:
- The DSC instrument and calibration method;
- Heating rate;
- Sample preparation;
- Atmospheric conditions;
- Whether the measured event is an onset, peak, or broad transition; and
- The reproducibility of the reported thermal event.
A product may satisfy claim 1 while falling outside claims 2 and 3. Conversely, a generic applicant should not assume that a different reported DSC value avoids claim 1, because claim 1 does not contain a DSC limitation.
XRPD claims
Claim 4 requires an XRPD pattern comprising peaks at approximately:
Claim 5 adds peaks at approximately:
- 11.0° 2θ;
- 15.9° 2θ; and
- 20.2° 2θ.
The use of “comprises” is significant. It generally indicates that the listed peaks must be present but does not exclude additional peaks. Claim 5 is therefore not limited to a pattern containing only the five listed reflections.
The XRPD claims raise the usual solid-state infringement questions:
- Whether peak positions fall within the stated ±0.2° tolerances;
- Whether relative intensities are material;
- Whether polymorph mixtures satisfy the claim;
- Whether amorphous material or hydrates are excluded;
- Whether preferred orientation changes the observed pattern; and
- Whether the accused sample is representative of the commercial batch.
Claims 4 and 5 are narrower than claim 1 and may be more vulnerable to design-around through a different polymorph, solvate, amorphous form, or salt form. They can still be commercially important because the marketed API may correspond to the characterized crystalline material described in the patent.
What formulations are protected by claims 6 through 16?
Claims 6 through 10 and 14 through 16 cover compositions containing TAF hemifumarate with a fumaric acid-to-TAF ratio centered on 0.5.
The numerical limitations are:
| Claim |
Ratio limitation |
| 6 |
0.5 ± 0.1, approximately 0.4 to 0.6 |
| 7 |
0.5 ± 0.05, approximately 0.45 to 0.55 |
| 8 |
0.5 ± 0.01, approximately 0.49 to 0.51 |
| 9 |
“About 0.5” |
| 10, 14-16 |
Dependent solid-composition limitations |
Claims 6 through 9 are composition claims rather than pure-salt claims. They may cover bulk API, pharmaceutical intermediates, or finished formulations if the required ratio is present. Claims 10 and 14 through 16 expressly add a solid-state limitation.
Claim 11 covers a pharmaceutical composition comprising the hemifumarate and a pharmaceutically acceptable excipient. This is a conventional product claim that can reach tablets, capsules, powders, granules, or other dosage forms, depending on the construction of “pharmaceutical composition.”
Claim 12 adds an additional therapeutic agent. Claim 13 identifies broad categories of HIV medicines, including:
- HIV protease inhibitors;
- Non-nucleoside reverse transcriptase inhibitors;
- Nucleoside and nucleotide reverse transcriptase inhibitors;
- Integrase inhibitors; and
- CCR5 inhibitors.
The claim language is broad at the class level. It does not identify particular active ingredients, strengths, ratios, release profiles, or tablet architectures.
Which marketed drugs are commercially relevant to this patent?
Tenofovir alafenamide is used in products for HIV and chronic HBV. Relevant Gilead products include:
| Product |
Primary indication |
TAF role |
| Vemlidy |
Chronic hepatitis B |
TAF product for HBV |
| Descovy |
HIV treatment and pre-exposure prophylaxis in approved populations |
TAF with emtricitabine |
| Biktarvy |
HIV treatment |
TAF with emtricitabine and bictegravir |
| Genvoya |
HIV treatment |
TAF with emtricitabine, elvitegravir and cobicistat |
| Odefsey |
HIV treatment |
TAF with emtricitabine and rilpivirine |
The FDA approved Vemlidy in November 2016 for chronic HBV infection in adults and, subsequently, certain pediatric patients. FDA-approved labeling identifies tenofovir alafenamide as the active antiviral component.[2]
The relevance of Patent 8,754,065 differs by product. For Vemlidy, the patent is directly relevant to the TAF salt and HBV method claims. For combination HIV products, the patent may overlap with the TAF component, but the complete product claim set can also depend on separate patents covering the combination, other active ingredients, dosage forms, or treatment regimens.
What is the Orange Book status of U.S. Patent 8,754,065?
The Orange Book lists patents and regulatory exclusivities for approved drug products, not for an active ingredient in the abstract. A patent may therefore be relevant to several TAF products but listed against only particular products and approved uses.
The practical Orange Book questions are:
- Whether U.S. Patent 8,754,065 is listed for Vemlidy.
- Whether it is listed for Descovy, Biktarvy, Genvoya or Odefsey.
- Which FDA use code accompanies the listing.
- Whether the listing is active, expired, delisted or subject to a corrected expiration date.
- Whether an ANDA applicant must address the patent through Paragraph I, II, III or IV certification.
A Paragraph IV certification would assert that the listed patent is invalid, unenforceable or will not be infringed by the proposed generic. The certification could trigger a patent-infringement action under 21 U.S.C. § 355(j)(5)(B)(iii), potentially creating a 30-month stay of approval if the brand owner or patent holder files suit within the statutory period.[3]
The supplied claim text does not establish the current Orange Book listing status or the specific use codes for Patent 8,754,065. Patent documents themselves do not determine Orange Book listing status.
When does U.S. Patent 8,754,065 lose exclusivity?
The patent’s expected ordinary expiration is in 2032. The relevant timeline is:
| Event |
Date or period |
| Earliest claimed priority |
2011 |
| U.S. application filing |
September 28, 2012 |
| Patent issuance |
June 17, 2014 |
| Expected ordinary expiration |
2032, based on the application-based patent term |
| Vemlidy FDA approval |
November 2016 |
| Vemlidy five-year NCE exclusivity period, if applicable |
Approximately through November 2021 |
| Generic entry assessment |
Requires Orange Book and litigation review |
U.S. patent term generally runs 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment and terminal disclaimers.[4] A precise expiration date should be taken from the current USPTO patent record and applicable Orange Book entry rather than inferred only from the issue date.
Regulatory exclusivity and patent exclusivity are separate. FDA exclusivity may delay approval of an ANDA or 505(b)(2) application even when no patent blocks approval. Patent expiry may occur after regulatory exclusivity ends, leaving the patent as the principal remaining barrier.
How strong is the patent estate for tenofovir alafenamide?
Patent 8,754,065 has a strong core claim and several narrower fallback positions.
Strengths
Claim 1 is a direct salt claim. If valid and enforceable, it can cover the commercially relevant TAF hemifumarate regardless of the manufacturer’s crystallization route.
The patent also contains multiple claim types:
- Composition of matter;
- Solid-state characterization;
- Pharmaceutical composition;
- Combination therapy;
- HIV treatment;
- HBV treatment; and
- Manufacturing process.
That diversification makes a complete design-around more difficult. A generic manufacturer may avoid one claim category while remaining exposed under another.
The process claims are useful because they identify seeded crystallization from defined solvent systems at controlled temperatures. Acetonitrile is expressly identified in claims 28 and 31, and claim 31 permits up to about 50% methylene chloride by volume.
Vulnerabilities
The claims may face validity and enforcement challenges involving:
- Anticipation or obviousness based on earlier TAF salt, fumarate or crystallization disclosures;
- Inherency disputes over whether prior-art TAF preparations formed the same hemifumarate;
- Ambiguity in the meaning of “hemifumarate”;
- Reproducibility of DSC and XRPD measurements;
- Written-description support for the full scope of the salt and ratio claims;
- Enablement of the broad composition and treatment claims; and
- Whether a process accused of infringement performs every required crystallization step.
Claims 2 through 5 are analytically dependent on test conditions. Minor changes in measurement protocol can affect DSC onset values and XRPD peak positions. Claims 6 through 9 also create potential disputes over sampling, assay methodology, water content, residual fumaric acid and whether the ratio is calculated on a molar or mass basis.
What manufacturing and intellectual-property barriers does the patent create?
Claims 27 through 31 are directed to preparing TAF hemifumarate by combining:
- An aprotic organic solvent;
- Fumaric acid;
- Tenofovir alafenamide; and
- One or more hemifumarate seed crystals.
The process then requires crystallization of additional hemifumarate. Claim 28 specifically identifies acetonitrile. Claim 30 lists a broad solvent group, including water, isopropyl alcohol, acetone, acetonitrile, toluene, ethyl acetate, isopropyl acetate, heptane, tetrahydrofuran and ketone solvents. Claim 31 narrows the solvent to acetonitrile with up to about 50% methylene chloride.
A generic API supplier could seek to avoid these claims by:
- Using a different salt-forming process;
- Omitting intentional hemifumarate seeding;
- Using a solvent system outside the listed limitations;
- Forming the salt through a different solvent exchange or antisolvent process;
- Producing a different solid form; or
- Purchasing API from a supplier with a non-infringing manufacturing route.
Process design-around does not avoid claim 1 if the resulting product is still TAF hemifumarate. It only addresses process-claim exposure.
Which companies are challenging tenofovir alafenamide exclusivity?
Generic competition is product-specific. A company seeking approval for a generic TAF product must address the patents listed for the relevant reference product, not every patent associated with the broader TAF molecule.
Potential applicants may include large generic manufacturers, specialty API producers and suppliers of fixed-dose antiretroviral combinations. The existence of an ANDA, Paragraph IV certification, patent suit or settlement cannot be established from the claim text supplied here.
For Vemlidy, an ANDA applicant would face a product-specific assessment of:
- Orange Book-listed patents;
- FDA use codes;
- Patent expiration dates;
- Paragraph IV certifications;
- Any 30-month stay;
- Pediatric exclusivity;
- Settlement restrictions; and
- The scope of the proposed label.
For combination products, the applicant would also need to analyze patents covering emtricitabine, bictegravir, rilpivirine, elvitegravir, cobicistat and the applicable fixed-dose formulation.
What litigation and settlement issues affect this patent?
The main litigation pathways are:
Paragraph IV litigation
A generic applicant could argue that the TAF hemifumarate claims are invalid or not infringed. The most likely technical disputes would concern prior-art salt formation, the claimed stoichiometry, polymorphism and the identity of the API in the proposed product.
Section viii carve-out
If the patent is listed only for a method of use, an ANDA applicant may attempt to omit the patented indication from its labeling. This route is less useful where the patent is a composition-of-matter claim to the API salt.
505(b)(2) litigation
A 505(b)(2) applicant using TAF hemifumarate but relying partly on FDA’s findings for an existing product may face patent certifications and potential litigation similar to an ANDA applicant.
Settlements
A settlement could establish a licensed entry date before patent expiry, subject to antitrust scrutiny and FDA filing requirements. The claim set alone provides no evidence of a settlement agreement, authorized-generic arrangement or license involving Patent 8,754,065.
How does Patent 8,754,065 compare with biosimilar risk?
Biosimilar risk is not applicable to TAF hemifumarate. Tenofovir alafenamide is a synthetic small molecule, not a biologic. Competition would proceed through the ANDA or, in some circumstances, 505(b)(2) pathway rather than the biosimilar pathway under the Public Health Service Act.
The relevant competitive risks are:
- Generic TAF hemifumarate;
- Generic Vemlidy-equivalent products;
- Fixed-dose HIV combinations;
- Alternative tenofovir products;
- Other nucleoside or nucleotide antiviral regimens; and
- Competing HBV therapies.
What geographic coverage does the patent provide?
U.S. Patent 8,754,065 provides territorial protection in the United States only. Corresponding patent-family members may protect TAF hemifumarate, formulations or processes in Europe, Japan, Canada, Australia and other markets. Each jurisdiction may differ in:
- Claim scope;
- Patent term;
- Supplementary protection certificate availability;
- Validity history;
- Opposition outcomes;
- Regulatory linkage;
- Use-claim enforceability; and
- Generic launch rules.
A U.S. non-infringement conclusion does not establish freedom to operate in Europe or other markets. Conversely, expiration or revocation of a foreign family member does not affect the U.S. patent.
What generic launch scenarios exist?
Three launch scenarios are commercially plausible:
| Scenario |
Effect |
| Launch after patent expiry |
Lowest litigation exposure, but delayed market entry |
| Paragraph IV launch after successful challenge or settlement |
Earlier entry, with litigation and damages risk |
| Non-infringing alternative formulation or salt |
Possible earlier entry, but claim 1 creates a major barrier if the product remains TAF hemifumarate |
A product using TAF hemifumarate is most exposed to claim 1. A product using a different salt may avoid claim 1 but could face separate patents directed to TAF formulations, combinations, dosage forms or therapeutic uses.
Key Takeaways
- U.S. Patent 8,754,065 is centered on tenofovir alafenamide hemifumarate.
- Claim 1 is the broadest and most commercially important claim.
- Claims 2 through 5 protect narrower DSC and XRPD-defined material.
- Claims 6 through 16 cover approximately 0.5:1 fumaric acid-to-TAF compositions and pharmaceutical formulations.
- Claims 17 through 25 cover HIV and HBV treatment methods.
- Claims 27 through 31 target seeded crystallization processes, particularly solvent systems using acetonitrile.
- The patent is expected to remain relevant through 2032, subject to the official USPTO term record.
- TAF is a small molecule, so biosimilar competition is not applicable.
- Generic risk depends on the Orange Book listing for the relevant reference product, the proposed product’s salt and solid form, and any Paragraph IV litigation or settlement.
- The claim text alone does not establish current litigation, settlement, Orange Book or ANDA status.
FAQs
Does Patent 8,754,065 cover Vemlidy?
It may be relevant to Vemlidy because Vemlidy contains tenofovir alafenamide. Direct product coverage depends on the identity of the marketed salt, the applicable patent listing and the scope of the approved product.
Can a generic avoid Patent 8,754,065 by using a different TAF polymorph?
A different polymorph may avoid the XRPD and DSC claims, but it may still fall within claim 1 if it is chemically tenofovir alafenamide hemifumarate.
Does the patent cover tenofovir disoproxil fumarate?
No. The claims are directed to tenofovir alafenamide hemifumarate, a different prodrug and salt from tenofovir disoproxil fumarate.
Are the process claims limited to acetonitrile?
No. Claim 28 identifies acetonitrile, while claim 30 lists multiple solvents. Claim 31 specifically addresses acetonitrile with up to about 50% methylene chloride.
Does once-daily dosing create a separate patent barrier?
Claims 23 and 25 expressly recite single-daily dosing for HIV and HBV treatment, respectively. Their practical value depends on the validity of the underlying method claim and whether the proposed product label includes the claimed dosing regimen.
References
- U.S. Patent and Trademark Office. (2014). U.S. Patent No. 8,754,065, Tenofovir alafenamide hemifumarate.
- U.S. Food and Drug Administration. (2023). Vemlidy prescribing information. Gilead Sciences, Inc.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Patent and Trademark Office. (2024). Patent term adjustment and patent term calculation guidance.
